Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2026-04-07 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. It is a letter from the Registrar and Share Transfer Agent confirming dematerialisation of securities and related compliance. The document is short (3503 characters) and serves as a regulatory confirmation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report but a compliance confirmation letter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2026-04-07 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release from Emcure Pharmaceuticals announcing a price reduction for their drug Poviztra®. It is addressed to stock exchanges and is titled 'Press Release'. The content focuses on the pricing change and market access strategy, with no financial statements, regulatory filings, or detailed financial data. It is not an earnings release or financial report but a corporate communication to the market. Therefore, it fits best under the category of a Capital/Financing Update (CAP) as it relates to pricing strategy impacting market and capital considerations, rather than a financial report or regulatory filing.
2026-04-02 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding an acquisition and subsequent amalgamation involving the company's step-down subsidiary. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content includes detailed disclosures about the acquisition of Cutimed Inc. and its amalgamation with Mantra Pharma Inc., including financial figures, rationale, and regulatory compliance. There is no financial report or earnings data presented; rather, it is an announcement of a corporate event (acquisition and amalgamation) with regulatory disclosures. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions and amalgamations.
2026-04-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter from Emcure Pharmaceuticals Limited addressed to stock exchanges, informing about the closure of the trading window for insiders ahead of the announcement of audited financial results for the quarter and financial year ending March 31, 2026. It references regulatory compliance with insider trading regulations and mentions that the date of the board meeting for approval of results will be intimated later. The document does not contain any financial data, results, or detailed report content. It is a notification related to trading restrictions prior to financial results announcement, not the results or report itself. The document length is short (2273 characters) and serves as an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2026-03-30 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement about the Notice of Postal Ballot. It references compliance with SEBI regulations and confirms the dispatch of the Notice of Postal Ballot. The document is short (2405 characters) and primarily serves as an announcement of the publication of a notice rather than the notice itself or the results of the postal ballot. There is no financial data, management discussion, or detailed report content. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Declaration of Voting Results or Proxy Solicitation, since it only confirms the dispatch and publication of the notice, not the voting results or solicitation materials themselves.
2026-03-25 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a Postal Ballot issued by Emcure Pharmaceuticals Limited, dated March 24, 2026. It is addressed to stock exchanges and shareholders, informing them about the remote e-voting process for the appointment of an Independent Director. The document references compliance with SEBI Listing Regulations, the Companies Act, and related circulars. It includes procedural details about voting, cut-off dates, and the resolution to be passed. There are no financial statements or earnings data, nor is this a transcript or presentation. It is not an announcement of voting results but the notice and explanatory statement for the voting process itself. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contained results, but here it is the notice for voting. The correct classification is Proxy Solicitation & Information Statement (PSI), as it is a material sent to shareholders to provide information and request votes for a meeting or resolution via postal ballot.
2026-03-24 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.